Israeli clinical-AI company Aidoc has received FDA 510(k) clearance for a CT-based triage and notification platform that can flag 14 distinct critical findings on a single abdominal CT scan, broadening one of the most widely deployed radiology AI products in the United States.
Fourteen findings, one scan
The cleared platform analyses an abdominal CT and alerts the radiologist when it detects signs of liver injury, spleen injury, bowel obstruction, appendicitis and 10 other emergent conditions covered by the submission. The goal is to prioritise studies in the worklist so that life-threatening findings reach a radiologist within minutes rather than hours, especially in busy emergency department settings.
From single-condition tools to system-wide triage
Earlier-generation radiology AI products typically cleared one or two findings at a time — a stroke flag, a pulmonary embolism flag, an intracranial-hemorrhage flag. Aidoc's multi-indication CT clearance reflects the regulatory shift toward whole-organ AI software-as-a-medical-device, where a single algorithm package can triage many conditions on the same study and integrate into a hospital's existing PACS and worklist.
FDA AI footprint keeps growing
The clearance lands as radiology continues to dominate FDA's AI-enabled medical device authorisations. The agency's running list now includes more than 1,200 cleared AI devices, with radiology applications accounting for roughly three-quarters of the total — a category in which Aidoc, along with vendors like Philips and others, has been a sustained contributor.
Where this fits in Aidoc's roadmap
Aidoc says its broader platform now spans more than a dozen FDA-cleared modules across the abdomen, chest, head and spine, used in over 1,500 hospitals worldwide. The company has been pushing toward a model in which one always-on AI layer sits between the scanner and the worklist, flagging anomalies regardless of the original ordering question.
Reporting based on coverage from Diagnostic Imaging, STAT News and FDA filings.